Detalles de la búsqueda
1.
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting.
Oncologist
; 29(1): e118-e130, 2024 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37603442
2.
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
Oncologist
; 2024 Mar 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38520745
3.
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
Br J Cancer
; 127(3): 383-393, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35264788
4.
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
Oncologist
; 27(2): 87-e115, 2022 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35641222
5.
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.
Future Oncol
; 17(19): 2513-2527, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33988036
6.
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Oncologist
; 24(8): 1128-1136, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31015312
7.
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.
Oncologist
; 23(10): 1178-1187, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29739893
8.
Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients.
Front Immunol
; 15: 1308109, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38348046
9.
Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis.
Front Immunol
; 15: 1353889, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38322260
10.
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 25(3): 233-243.e8, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38105153
11.
EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience.
J Thorac Dis
; 14(9): 3364-3375, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36245580
12.
The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments.
Cancers (Basel)
; 14(22)2022 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36428792
13.
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.
Eur J Cancer
; 167: 142-148, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35307254
14.
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.
Transl Lung Cancer Res
; 10(1): 202-220, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33569305
15.
Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors.
Front Oncol
; 10: 607840, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33520716
16.
Novel Nuclear Medicine Imaging Applications in Immuno-Oncology.
Cancers (Basel)
; 12(5)2020 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32455666
17.
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
Clin Lung Cancer
; 21(1): 1-14.e3, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31601525
18.
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer.
Transl Lung Cancer Res
; 9(5): 1810-1821, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33209603
19.
Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?
Crit Rev Oncol Hematol
; 138: 87-103, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31092389
20.
Corrigendum to "Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?" [Crit. Rev. Oncol. Hematol. 138 (June) (2019), 87-103].
Crit Rev Oncol Hematol
; 140: 73, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31176852
Resultados
1 -
20
de 20
1
Próxima >
>>